Gain of function mutations in PIK3CA, the gene encoding phosphoinositide-(3)-kinase α (PI3Kα), occurs in ~30–40% of advanced estrogen receptor positive (ER+) breast cancers and has been associated with poor prognosis2. This evidence concerns the gene ESR1 and breast cancer.